Literature DB >> 10364769

Advances in the medical management of acute coronary syndromes.

C P Cannon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10364769     DOI： 10.1023/a:1008841721975

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  134 in total

1.  Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.

Authors: 
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

2.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

3.  GUSTO, TIMI and the case for rapid reperfusion.

Authors:  C P Cannon; E Braunwald
Journal:  Acta Cardiol       Date:  1994       Impact factor: 1.718

4.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

5.  Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.

Authors:  J Hirsh; V Fuster
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

8.  Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.

Authors: 
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

9.  New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.

Authors:  C R Benedict; C J Refino; B A Keyt; R Pakala; N F Paoni; G R Thomas; W F Bennett
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

10.  Intracoronary thrombolysis in evolving myocardial infarction.

Authors:  W Ganz; N Buchbinder; H Marcus; A Mondkar; J Maddahi; Y Charuzi; L O'Connor; W Shell; M C Fishbein; R Kass; A Miyamoto; H J Swan
Journal:  Am Heart J       Date:  1981-01       Impact factor: 4.749
View more
  2 in total

1.  The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.

Authors:  Nimish N Vachharajani; Ralph H Raymond; Wen-Chyi Shyu; Bruce C Stouffer; David W Boulton
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.